Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T15:56:34.972Z.
Consensus retrieved: 2026-10-06T12:06:21.719Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T15:56:34.972Z.
Quote observation: 2026-10-06T15:55:06.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 26a6c2e450689c32f4e4e5954cf906f309ed45562a8b136dc87c806878a45fac
Forward PE Ratio (N/A) = Dated Quote Price ($141.13) / Consensus Forward EPS ($-9.62)
FORWARD PE RATIO
N/A
GRAIL Inc.
Market Cap
$6.06B
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| GRAIL Inc. (GRAL) | $6.06B | N/A |
| Ligand Pharmaceuticals Incorporated (LGND)vs › | $6.02B | 32.28 |
| Iovance Biotherapeutics, Inc. (IOVA)vs › | $5.94B | N/A |
| CG Oncology Inc. (CGON)vs › | $5.83B | N/A |
| Kiniksa Pharmaceuticals International, plc (KNSA)vs › | $5.82B | 54.80 |
| MiniMed Group, Inc. Common Stock (MMED)vs › | $5.55B | 29.33 |
| RadNet, Inc. (RDNT)vs › | $5.54B | 136.89 |
| Lantheus Holdings, Inc. (LNTH)vs › | $6.51B | 18.47 |
| Amneal Pharmaceuticals, Inc. (AMRX)vs › | $6.56B | 20.05 |
| Hims & Hers Health, Inc. (HIMS)vs › | $6.60B | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $141.13, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-9.62 | $-10.27 – $-9.04 | 5 | n/m |
| 2027-12-31 | $-10.20 | $-10.56 – $-9.78 | 5 | n/m |
| 2028-12-31 | $-9.72 | $-12.04 – $-8.28 | 8 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
